

“CSC × 24 hrs” to represent Skp2 protein expression in CTCL Patients  
 > Six band images from Figure 5B in a paper published in *Biochemistry*<sup>1</sup> to represent Actin protein expression in eight (8) CTCL Patients, one (1) T-ALL Patient, and two (2) normal subjects in Figure 1 of *JCI* 2011 and Figure 3 (bottom panel) in R01 CA122737-01A2

- In Figure 8B (bottom part) in *JCI* 2011, also included as Figure 9 in R01 CA122737-01A2 and Slide 29 in the CREST Presentation, respondent falsely reused  $\beta$ -actin, Laminin B, alpha-tubulin, GFP-Pro-IL-16 and HSC70 band images of “Knockdown of HSC70 in Jurkat cells and Hut78 cells” as from Normal Human Patient and Normal Subject T-cells.

- In Figure 14A in R01 CA122737-01A2, respondent falsely reused GFP-Pro-IL-16 band images of “Knockdown of HSC70 in Jurkat cells” as AKT and phospho-AKT expression and the nuclear Pro-IL-16 band images from Figure 5B in *Biochemistry* 2002 as FOXO1 protein expression in human T-cells stimulated with IL-16.

- In Figure 14B in R01 CA122737-01A1 and R01 CA122737-01A2, respondent falsely reused band images from Figure 5B in *Biochemistry* 2002 that represents Anti-pro IL6 and Anti-Tubulin to represent FOXO1 protein expression in human T-cells.

- In Figure 9 in *JCI* 2011, respondent falsely reused band images representing CD26-T cells of CTCL Patient to also represent normal human subject control for CD26+ and control for CD26-T cells in the same figure.

- In Figure 5 in R01 CA122737-01A1, also included as Figure 4 in R01 CA122737-01A2, respondent reused and falsely relabeled band images within the same figure to represent different experimental conditions.

Respondent intentionally, knowingly, and recklessly falsified and/or fabricated Western blot data for siRNA knockdown of Heat shock cognate 71 kDa protein (HSC70) in Jurkat cells purportedly with two different siRNA constructs, by reusing and relabeling ten (10) band images from experiments on Hut78 cells and a failed experiment in Jurkat cells, and included them in four (4) figures in one manuscript, one published paper, one grant application, and one presentation.

Specifically, respondent reused band images of an unpublished Western blot figure, by:

- Reusing results of a single HSC70 siRNA knockdown on Hut78 cells and relabeling them to represent data from Jurkat cells in Figure 6 in the first submission of the *JCI* manuscript, Figure 6 in *JCI* 2011, and Figure 10 in R01 CA122737-01A2 (also included as Slide 27 in the CREST Presentation)
- reusing results for a second siRNA construct that failed to knockdown HSC70 in Jurkat cells and relabeling them as from control samples in Figure 6 in *JCI* 2011

Dr. Cruikshank entered into a Voluntary Exclusion Agreement (Agreement) and voluntarily agreed for a period of five (5) years, beginning on May 13, 2019:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS’ Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”); and

(2) to exclude himself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

**Wanda K. Jones,**

*Interim Director, Office of Research Integrity.*

[FR Doc. 2019-10874 Filed 5-23-19; 8:45 am]

**BILLING CODE 4150-31-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors, June 10, 2018, 8:30 a.m. to June 11, 2018, 12:00 p.m., National Cancer Institute Shady Grove Campus, Rockville, MD 20850 which was published in the **Federal Register** on February 11, 2019, 84 FR 3312.

This meeting notice is amended to add two subcommittee meetings on Sunday, June 9, 2019. The National Cancer Advisory Board (NCAB) Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities will meet on June 9, 2019 from 5:30 p.m. to 7:00 p.m. and the NCAB Subcommittee on Planning and Budget will meet on June 9, 2019 from 7:30 p.m. to 9:00 p.m. at

the Gaithersburg Marriott Washingtonian Center, 9751 Washington Boulevard, Room—To Be Determined, Gaithersburg, MD 20878.

This meeting notice is also amended to change the meeting from a two-day to a one-day meeting, correct the year, and change the closed session agenda. The joint meeting of the NCAB and NCI Board of Scientific Advisors will now be held on June 10, 2019 with the open session from 8:30 a.m. to 4:45 p.m. and the closed session from 5:00 p.m. to 6:00 p.m. The closed session agenda is corrected to be the Review of NCAB grant applications. The meeting is partially Closed to the public.

Dated: May 21, 2019.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-10943 Filed 5-23-19; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be held as a teleconference only and is open to the public to dial-in for participation. Individuals who plan to dial-in to the meeting and need special assistance or other reasonable accommodations in order to do so, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* National Cancer Institute Clinical Trials and Translational Research Advisory Committee; Translational Research Strategy Subcommittee (TRSS).

*Date:* June 19, 2019,

*Time:* 10:00 a.m. to 11:00 a.m.

*Agenda:* Review the Glioblastoma (GBM) Working Group Report.

*Place:* National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Telephone Conference Call), Phone: 240-276-6500, Conference Code: 1102766460, Passcode: 6460.

*Contact Person:* Peter Ujhazy, MD, Ph.D., Deputy Associate Director, Translational Research Program, Division of Cancer Treatment and Diagnosis, National Institutes of Health, National Cancer Institute, 9609 Medical Center Drive, Room 3W106, Rockville, MD 20850, 240-276-5681, [ujhazy@mail.nih.gov](mailto:ujhazy@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on

<sup>1</sup> Wilson KC, Cruikshank WW, Center DM, Zhang Y. Pinterleukin-16 contains a functional CcN motif that regulates nuclear localization. *Biochemistry* 2002;41:14306-14312 (hereafter referred to as “*Biochemistry* 2002”).